The past decade has seen tremendous efforts in biomarker discovery and validation for
neurodegenerative diseases. The source and type of biomarkers has continued to grow for …

Recent revisions to the diagnostic criteria for Alzheimer's disease (AD) incorporated
conceptual advances in the field. Specifically, AD is now recognized to encompass a …

Ante-mortem diagnosis of neurodegenerative disorders based on clinical features alone is
associated with variable sensitivity and specificity, and biomarkers can potentially improve …

Measures of the severity of cognitive impairment or parkinsonism are the usual endpoints in
clinical trials for Alzheimer's disease (AD) and Parkinson's disease (PD), but are critically …

Rapid progress towards understanding the molecular underpinnings of neurodegenerative
disorders such as Alzheimer's disease is revolutionizing drug discovery for these conditions …

Alzheimer's disease (AD) is a progressive neurodegenerative disorder that slowly destroys
memory and thinking skills, resulting in behavioral changes. It is estimated that nearly 36 …

Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease,
amyotrophic lateral sclerosis, and frontotemporal dementia have several important features …

Biomarker research is a rapidly advancing field in medicine. Recent advances in genomic,
genetic, epigenetic, neuroscientific, proteomic, and metabolomic knowledge and …

The diagnosis of neurodegenerative diseases within neurology and psychiatry are
hampered by the difficulty in getting biopsies and thereby validating the diagnosis by …

Molecular diagnostics provide a powerful method to detect and diagnose various
neurological diseases such as Alzheimer's and Parkinson's disease. The confirmation of …